NasdaqCM - Delayed Quote USD

DURECT Corporation (DRRX)

0.8434 +0.0384 (+4.77%)
At close: April 23 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. James E. Brown D.V.M. Co-Founder, CEO, President & Director 633.46k -- 1957
Mr. Timothy M. Papp M.B.A. CFO & Secretary 427.62k -- 1976
Dr. Norman L. Sussman M.D. Chief Medical Officer 471.71k -- 1953
Ms. Judy R. Joice Senior Vice President of Operations & Corporate Quality Assurance 451.82k -- 1957
Dr. WeiQi Lin M.D., Ph.D. Executive VP of Research & Development and Principal Scientist -- -- --
Mr. Keith L. Lui M.B.A. Senior Vice President of Business Development, Commercial & Medical Affairs -- -- --
Ms. Jian Li M.B.A. Senior VP of Finance, Corporate Controller & Secretary 297.08k 16.41k 1970
Dr. Su Il Yum Ph.D. Executive Officer 331.74k 62.44k 1939

DURECT Corporation

10240 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417 https://www.durect.com
Sector: 
Healthcare
Full Time Employees: 
58

Description

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Corporate Governance

DURECT Corporation’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 7; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
DURECT Corporation Earnings Call

Related Tickers